Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 43

1.

Copper Ions and Parkinson's Disease: Why Is Homeostasis So Relevant?

Bisaglia M, Bubacco L.

Biomolecules. 2020 Jan 29;10(2). pii: E195. doi: 10.3390/biom10020195. Review.

2.

Antioxidant Therapy in Parkinson's Disease: Insights from Drosophila melanogaster.

De Lazzari F, Sandrelli F, Whitworth AJ, Bisaglia M.

Antioxidants (Basel). 2020 Jan 7;9(1). pii: E52. doi: 10.3390/antiox9010052. Review.

3.

Superoxide Dismutases SOD1 and SOD2 Rescue the Toxic Effect of Dopamine-Derived Products in Human SH-SY5Y Neuroblastoma Cells.

Biosa A, De Lazzari F, Masato A, Filograna R, Plotegher N, Beltramini M, Bubacco L, Bisaglia M.

Neurotox Res. 2019 Nov;36(4):746-755. doi: 10.1007/s12640-019-00078-y. Epub 2019 Jun 21.

PMID:
31228093
4.

Circadian Rhythm Abnormalities in Parkinson's Disease from Humans to Flies and Back.

De Lazzari F, Bisaglia M, Zordan MA, Sandrelli F.

Int J Mol Sci. 2018 Dec 6;19(12). pii: E3911. doi: 10.3390/ijms19123911. Review.

5.

Superoxide Radical Dismutation as New Therapeutic Strategy in Parkinson's Disease.

De Lazzari F, Bubacco L, Whitworth AJ, Bisaglia M.

Aging Dis. 2018 Aug 1;9(4):716-728. doi: 10.14336/AD.2017.1018. eCollection 2018 Aug. Review.

6.

Dopamine Oxidation Products as Mitochondrial Endotoxins, a Potential Molecular Mechanism for Preferential Neurodegeneration in Parkinson's Disease.

Biosa A, Arduini I, Soriano ME, Giorgio V, Bernardi P, Bisaglia M, Bubacco L.

ACS Chem Neurosci. 2018 Nov 21;9(11):2849-2858. doi: 10.1021/acschemneuro.8b00276. Epub 2018 Jul 3.

PMID:
29906101
7.

Diabetes Mellitus as a Risk Factor for Parkinson's Disease: a Molecular Point of View.

Biosa A, Outeiro TF, Bubacco L, Bisaglia M.

Mol Neurobiol. 2018 Nov;55(11):8754-8763. doi: 10.1007/s12035-018-1025-9. Epub 2018 Mar 28. Review.

PMID:
29594935
8.

Superoxide dismutating molecules rescue the toxic effects of PINK1 and parkin loss.

Biosa A, Sanchez-Martinez A, Filograna R, Terriente-Felix A, Alam SM, Beltramini M, Bubacco L, Bisaglia M, Whitworth AJ.

Hum Mol Genet. 2018 May 1;27(9):1618-1629. doi: 10.1093/hmg/ddy069.

9.

DJ-1 as a deglycating enzyme: A unique function to explain a multifaceted protein?

De Lazzari F, Bisaglia M.

Neural Regen Res. 2017 Nov;12(11):1797-1798. doi: 10.4103/1673-5374.219035. No abstract available.

10.

Recent findings on the physiological function of DJ-1: Beyond Parkinson's disease.

Biosa A, Sandrelli F, Beltramini M, Greggio E, Bubacco L, Bisaglia M.

Neurobiol Dis. 2017 Dec;108:65-72. doi: 10.1016/j.nbd.2017.08.005. Epub 2017 Aug 18. Review.

PMID:
28823929
11.

Superoxide Dismutase (SOD)-mimetic M40403 Is Protective in Cell and Fly Models of Paraquat Toxicity: IMPLICATIONS FOR PARKINSON DISEASE.

Filograna R, Godena VK, Sanchez-Martinez A, Ferrari E, Casella L, Beltramini M, Bubacco L, Whitworth AJ, Bisaglia M.

J Biol Chem. 2016 Apr 22;291(17):9257-67. doi: 10.1074/jbc.M115.708057. Epub 2016 Mar 7.

12.
13.

Anti-Oxidants in Parkinson's Disease Therapy: A Critical Point of View.

Filograna R, Beltramini M, Bubacco L, Bisaglia M.

Curr Neuropharmacol. 2016;14(3):260-71. Review.

14.

Analysis of the Catecholaminergic Phenotype in Human SH-SY5Y and BE(2)-M17 Neuroblastoma Cell Lines upon Differentiation.

Filograna R, Civiero L, Ferrari V, Codolo G, Greggio E, Bubacco L, Beltramini M, Bisaglia M.

PLoS One. 2015 Aug 28;10(8):e0136769. doi: 10.1371/journal.pone.0136769. eCollection 2015.

15.

The chaperone-like protein 14-3-3η interacts with human α-synuclein aggregation intermediates rerouting the amyloidogenic pathway and reducing α-synuclein cellular toxicity.

Plotegher N, Kumar D, Tessari I, Brucale M, Munari F, Tosatto L, Belluzzi E, Greggio E, Bisaglia M, Capaldi S, Aioanei D, Mammi S, Monaco HL, Samo B, Bubacco L.

Hum Mol Genet. 2014 Nov 1;23(21):5615-29. doi: 10.1093/hmg/ddu275. Epub 2014 Jun 3.

PMID:
24895406
16.

DJ-1 is a copper chaperone acting on SOD1 activation.

Girotto S, Cendron L, Bisaglia M, Tessari I, Mammi S, Zanotti G, Bubacco L.

J Biol Chem. 2014 Apr 11;289(15):10887-99. doi: 10.1074/jbc.M113.535112. Epub 2014 Feb 24.

17.

Biophysical groundwork as a hinge to unravel the biology of α-synuclein aggregation and toxicity.

Plotegher N, Greggio E, Bisaglia M, Bubacco L.

Q Rev Biophys. 2014 Feb;47(1):1-48. doi: 10.1017/S0033583513000097. Epub 2014 Jan 21. Review.

PMID:
24443929
18.

Are dopamine derivatives implicated in the pathogenesis of Parkinson's disease?

Bisaglia M, Filograna R, Beltramini M, Bubacco L.

Ageing Res Rev. 2014 Jan;13:107-14. doi: 10.1016/j.arr.2013.12.009. Epub 2014 Jan 3. Review.

PMID:
24389159
19.

Dysfunction of dopamine homeostasis: clues in the hunt for novel Parkinson's disease therapies.

Bisaglia M, Greggio E, Beltramini M, Bubacco L.

FASEB J. 2013 Jun;27(6):2101-10. doi: 10.1096/fj.12-226852. Epub 2013 Mar 5. Review.

PMID:
23463698
20.

Covalent α-synuclein dimers: chemico-physical and aggregation properties.

Pivato M, De Franceschi G, Tosatto L, Frare E, Kumar D, Aioanei D, Brucale M, Tessari I, Bisaglia M, Samori B, de Laureto PP, Bubacco L.

PLoS One. 2012;7(12):e50027. doi: 10.1371/journal.pone.0050027. Epub 2012 Dec 13.

Supplemental Content

Loading ...
Support Center